In particular, our data suggest that GPER is up-regulated in an EGFR-dependent manner in palbociclib-resistant BC cells, therefore contributing to the insensitivity of BC cells to this CDK4/6 inhibitor. This evidence concerns the gene EGFR and breast cancer.